Treatment of antiretroviral-drug-resistant HIV-1 infection

Lancet

Volumn 362, Issue 9400, 2003, Pages 2002-2011

  Deeks, Steven G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE; TIPRANAVIR; ZIDOVUDINE;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG TOXICITY; EMPIRICISM; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; PATHOGENESIS; PLASTICITY; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT WITHDRAWAL; VERTICAL TRANSMISSION; VIRUS LATENCY; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0347995130     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15022-2     Document Type: Review

References (90)

1. Mocroft A., Devereux H., Kinloch-de-Loes S., et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS. 14:2000;1545-1552.
2. Lucas G.M., Chaisson R.E., Moore R.D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 131:1999;81-87.
3. Deeks S.G., Hecht F.M., Swanson M., et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 13:1999;F35-43.
4. Deeks S.G., Barbour J.D., Martin J.N., Swanson M.S., Grant R.M. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 181:2000;946-953.
5. Richman DD, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 2001.
6. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
7. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
8. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 69:1995;5087-5094.
9. Wu T.D., Schiffer C.A., Gonzales M.J., et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol. 77:2003;4836-4847.
10. Jackson J.B., Becker-Pergola G., Guay L.A., et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 14:2000;F111-115.
11. Martinez-Picado J., Savara A.V., Sutton L., D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 73:1999;3744-3752.
12. Back N.K., Nijhuis M., Keulen W., et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:1996;4040-4049.
13. Goudsmit J., de Ronde A., de Rooij E., de Boer R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol. 71:1997;4479-4484.
14. Nijhuis M., Schuurman R., de Jong D., et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 13:1999;2349-2359.
15. Barbour J.D., Wrin T., Grant R.M., et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 76:2002;11104-11112.
16. Deeks S.G., Wrin T., Liegler T., et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 344:2001;472-480.
17. Devereux H.L., Emery V.C., Johnson M.A., Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol. 65:2001;218-224.
18. Finzi D., Blankson J., Siliciano J.D., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 5:1999;512-517.
19. Opravil M., Hirschel B., Lazzarin A., et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis. 185:2002;1251-1260.
20. Hermankova M., Ray S.C., Ruff C., et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 286:2001;196-207.
21. Albrecht M.A., Bosch R.J., Hammer S.M., et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 345:2001;398-407.
22. Ledergerber B., Egger M., Opravil M., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 353:1999;863-868.
23. Gulick R.M., Mellors J.W., Havlir D., et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 280:1998;35-41.
24. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 133:2000;21-30.
25. Bangsberg D.R., Hecht F.M., Charlebois E.D., et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 14:2000;357-366.
26. Nieuwkerk P.T., Sprangers M.A., Burger D.M., et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 161:2001;1962-1968.
27. Fletcher C.V., Acosta E.P., Cheng H., et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS. 14:2000;2495-24501.
28. Havlir D.V., Tierney C., Friedland G.H., et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis. 182:2000;321-325.
29. Mocroft A., Phillips A.N., Miller V., et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS. 15:2001;201-209.
30. Demeter L.M., Hughes M.D., Coombs R.W., et al. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. Ann Intern Med. 135:2001;954-964.
31. Mocroft A., Gill M.J., Davidson W., Phillips A.N. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 12:1998;2161-2167.
32. Durant J., Clevenbergh P., Garraffo R., et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 14:2000;1333-1339.
33. Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 15:2001;71-75.
34. Kim R.B., Fromm M.F., Wandel C., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 101:1998;289-294.
35. Aweeka F., Jayewardene A., Staprans S., et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol. 20:1999;39-43.
36. Solas C., Lafeuillade A., Halfon P., Chadapaud S., Hittinger G., Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 47:2003;238-243.
37. Phillips A.N., Staszewski S., Weber R., et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 286:2001;2560-2567.
38. Fellay J., Boubaker K., Ledergerber B., et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 358:2001;1322-1327.
39. Little S.J., Holte S., Routy J.P., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 347:2002;385-394.
40. Grant R.M., Hecht F.M., Warmerdam M., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 288:2002;181-188.
41. Yerly S., Vora S., Rizzardi P., et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS. 15:2001;2287-2292.
42. Leigh Brown A.J., Frost S.D., Mathews W.C., et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis. 187:2003;683-686.
43. Lampe F.C., Johnson M.A., Lipman M., et al. Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years. AIDS. 17:2003;768-770.
44. Havlir D.V., Hellmann N.S., Petropoulos C.J., et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 283:2000;229-234.
45. Descamps D., Flandre P., Calvez V., et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 283:2000;205-211.
46. Walmsley S., Bernstein B., King M., et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 346:2002;2039-2046.
47. Martinez-Picado J., DePasquale M.P., Kartsonis N., et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA. 97:2000;10948-10953.
48. Hammer S.M., Vaida F., Bennett K.K., et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 288:2002;169-180.
49. Lawrence J, Mayers D, Huppler Hullsiek K, et al. CPCRA 064: A randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA: 2003, abstr 67.
50. Katlama C, Dominguez S, Duvivier C, et al. Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097). Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA: 2003, abstr 68.
51. Gulick R.M., Hu X.J., Fiscus S.A., et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus- infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 182:2000;1375-1384.
52. Benson C.A., Deeks S.G., Brun S.C., et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 185:2002;599-607.
53. Hall C.S., Raines C.P., Barnett S.H., Moore R.D., Gallant J.E. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS. 13:1999;1207-1212.
54. Zolopa A.R., Shafer R.W., Warford A., et al. HIV-1 genotypic resistance patterns predict response to saquinavir- ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 131:1999;813-821.
55. DeGruttola V., Dix L., D'Aquila R., et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 5:2000;41-48.
56. Hsu A., Isaacson J., Brun S., et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 47:2003;350-359.
57. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 283:2000;2417-2426.
58. Harrigan P.R., Larder B.A. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob Agents Chemother. 46:2002;909-912.
59. Tebas P., Patick A.K., Kane E.M., et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS. 13:1999;F23-28.
60. Shulman N.S., Hughes M.D., Winters M.A., et al. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to Stavudine monotherapy in zidovudine-experienced patients. J Acquir Immune Defic Syndr. 31:2002;121-127.
61. Saah A.J., Haas D.W., DiNubile M.J., et al. Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. J Infect Dis. 187:2003;1157-1162.
62. D'Aquila R.T., Schapiro J.M., Brun-Vézinet F., et al. Drug resistance mutations in HIV-1. Top HIV Med. 10:2002;11-15.
63. Havlir D.V., Bassett R., Levitan D., et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 286:2001;171-179.
64. Cohen Stuart J.W., Wensing A.M., Kovacs C., et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 28:2001;105-113.
65. Ramratnam B., Mittler J.E., Zhang L., et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 6:2000;82-85.
66. Gunthard H.F., Frost S.D., Leigh-Brown A.J., et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol. 73:1999;9404-9412.
67. Sklar P.A., Ward D.J., Baker R.K., et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS. 16:2002;2035-2041.
68. Katlama C., Clotet B., Plettenberg A., et al. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. HIV Med. 2:2001;27-34.
69. Henry K., Wallace R.J., Bellman P.C., et al. Twice-daily triple nucleoside intensification treatment with lamivudine- zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. J Infect Dis. 183:2001;571-578.
70. Shulman N., Zolopa A., Havlir D., et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother. 46:2002;3907-3916.
71. Montaner J.S., Harrigan P.R., Jahnke N., et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS. 15:2001;61-69.
72. Youle M., Tyrer M., Fisher M., et al. Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. J Acquir Immune Defic Syndr. 29:2002;58-61.
73. Schooley R.T., Ruane P., Myers R.A., et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48- week, randomized, double-blind study. AIDS. 16:2002;1257-1263.
74. Duval X., Lamotte C., Race E., et al. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother. 46:2002;570-574.
75. Montaner J., Hill A., Acosta E. Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet. 357:2001;1438-1440.
76. Yeni P.G., Hammer S.M., Carpenter C.C., et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 288:2002;222-235.
77. Haubrich R.H., Kemper C.A., Hellmann N.S., et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 16:2002;F33-40.
78. Dybul M., Fauci A.S., Bartlett J.G., Kaplan J.E., Pau A.K. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 137:2002;381-433.
79. Kemper C.A., Witt M.D., Keiser P.H., et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 15:2001;609-615.
80. Mellors J.W., Rinaldo CR Jr, Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
81. Le Moing V., Thiebaut R., Chene G., et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis. 185:2002;471-480.
82. Stoddart C.A., Liegler T.J., Mammano F., et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 7:2001;712-718.
83. Deeks S.G., Hoh R., Grant R.M., et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 185:2002;315-323.
84. Piketty C., Weiss L., Thomas F., Mohamed A.S., Belec L., Kazatchkine M.D. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis. 183:2001;1328-1335.
85. Grabar S., Le Moing V., Goujard C., et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 133:2000;401-410.
86. Deeks S.G., Barbour J.D., Grant R.M., Martin J.N. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 16:2002;201-207.
87. Miller V., Sabin C., Hertogs K., et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 14:2000;2857-2867.
88. Izopet J., Massip P., Souyris C., et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS. 14:2000;2247-2255.
89. Devereux H.L., Youle M., Johnson M.A., Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS. 13:1999;F123-127.
90. Lalezari J.P., Henry K., O'Hearn M., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 348:2003;2175-2185.